APA (7th ed.) Citation

Masubuchi, K., Imai, H., Wasamoto, S., Tsuda, T., Minemura, H., Nagai, Y., . . . Minato, K. (2022). Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival. Thoracic Cancer, 13(19), 2776. https://doi.org/10.1111/1759-7714.14621

Chicago Style (17th ed.) Citation

Masubuchi, Ken, et al. "Post‐progression Survival After Atezolizumab Plus Carboplatin and Etoposide as First‐line Chemotherapy in Small Cell Lung Cancer Has a Significant Impact on Overall Survival." Thoracic Cancer 13, no. 19 (2022): 2776. https://doi.org/10.1111/1759-7714.14621.

MLA (9th ed.) Citation

Masubuchi, Ken, et al. "Post‐progression Survival After Atezolizumab Plus Carboplatin and Etoposide as First‐line Chemotherapy in Small Cell Lung Cancer Has a Significant Impact on Overall Survival." Thoracic Cancer, vol. 13, no. 19, 2022, p. 2776, https://doi.org/10.1111/1759-7714.14621.